Trusted Resources: Education
Scientific literature and patient education texts
Mucopolysaccharidosis Type II: A Kenyan Case Series
source: International journal of endocrinology
year: 2021
authors: Mungai LNW,Njeru CM,Nyamai LA,Maina M
summary/abstract:Hunter syndrome, or mucopolysaccharidosis type 2 (MPS2), is a lysosomal storage disorder associated with the involvement of multiple organs such as the central nervous system, hepatomegaly, musculoskeletal, respiratory, cardiac, and hearing. This is due to the accumulation of glycosaminoglycans in body tissues leading to organ failure. Since the laboratories in Kenya do not screen for metabolic diseases, there is the likelihood of assumption that these patients do not exist. These first cases were referred from the eastern part of Kenya where the majority of inhabitants are from the same ethnic community. It was noted that there was increased mortality among boys below the age of 20 years, and hence, the families sought for help in the national referral and teaching hospital. The case series is meant to show that these cases exist and the majority of the patients may be dying before the diagnosis is made. There are no data on MPS2 from Kenya, and the prevalence and incidence are unknown. In this retrospective study, we present a case series of 6 Kenyan boys with MPS2 from a national referral hospital. They were part of 17 patients who had had their blood analyzed for metabolic diseases. All of them were symptomatic with varying degrees of central nervous system involvement. They had undetectable levels of iduronate-2-sulfatase (I2S) enzyme, and three genetic mutations were detected in the IDS gene.
organization: University of Nairobi, Nairobi, Kenya.DOI: 10.1155/2021/2328402
read more
Related Content
-
Therapy-Type Related Long-Term Outcomes in Mucopolysaccaridosis Type II (Hunter Syndrome) – Case SeriesMucopolysaccharidosis type II (MPS II, H...
-
X-Linked Recessive Inheritance Pattern in MPS II (Hunter Syndrome)https://www.onempsvoice.com/wp-content/u...
-
Denali Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to ETV:IDS (DNL310) for the Treatment o...Denali Therapeutics Inc., a biopharmaceu...
-
Loss of Function of Mutant IDS Due to Endoplasmic Reticulum-Associated Degradation: New Therapeutic Opportunities fo...Mucopolysaccharidosis type II (MPS II) r...
-
Oliver and Sam (MPSII)Oliver and Samuel are brothers and they ...
-
What Is Hunter Syndrome?https://slideplayer.com/slide/6977723/...
-
Hunter Syndrome (MPS II): An Uncommon Combination of Childhood Complaintshttps://www.youtube.com/watch?v=7kBGEYAF...